Sangamo Therapeutics (SGMOQ) Change in Accured Expenses (2010 - 2025)

Sangamo Therapeutics has reported Change in Accured Expenses for 16 years, with the latest figure at -$1.2 million in Q4 2025.

• On a quarterly basis, Change in Accured Expenses rose 82.96% year-over-year to -$1.2 million in Q4 2025; TTM through Dec 2025 was $3.1 million, a 121.55% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 121.55% from the prior year.
• Change in Accured Expenses was -$1.2 million for Q4 2025 at Sangamo Therapeutics, down from $3.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $16.1 million in Q3 2022, with the low at -$8.6 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is -$906100.0, with a median of -$1.3 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses jumped 1210.72% in 2022, then slumped 1311.23% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$3.0 million in 2021, then soared by 231.7% to $3.9 million in 2022, then slumped by 291.29% to -$7.5 million in 2023, then increased by 2.03% to -$7.3 million in 2024, then surged by 82.96% to -$1.2 million in 2025.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q4 2025), $3.5 million (Q3 2025), and -$3.5 million (Q2 2025), per Business Quant data.